More'Uplifting' News on Breast Cancer Recurrences

Sometimes I wish they would stop researching breast cancer so we stop getting such'good'news. New research was meant to look at whether some hormone receptor positive breast cancer patientscould stop taking tamoxifen or aromatase inhibitors such as Femara, Aromasin, or Arimidex. However they found instead that ER/PR+ breast cancers can'smolder'(their word, not mine) for twenty years or more, before recurring.Aromatase inhibitors and tamoxifen inhibit the production of estrogen which feeds these ER/PR+ breast cancers. The longer you are on the medication, the longer you are protected from a recurrence. However, some women experience side effects and want to get off them as soon as possible. Other women have no problems and stay on them longer than the initial five years.“Even after 5 years of adjuvant endocrine therapy, women with ER-positive, early-stage breast cancer still had a persistent risk of recurrence and death from breast cancer for at least 20 years after the original diagnosis,” they wrote in their report, published in the New England Journal of Med icine.“Even though these women remained free of recurrence in the first five years, the risk of having their cancer recur elsewhere (for example in the bone, liver or lung) from years five to 20 remained constant,” Hayes said.I am so excited by this uplifting news. Maybe its time to stop reading the research unless my oncologist tells me about something new.
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: breast cancer treatment cancer research frustration Source Type: blogs

Related Links:

Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Di Meglio Survivors of early-stage breast cancer may report treatment-related side effects that persist for several years after the end of primary treatment. Among these, fatigue and cognitive disorders are frequent complaints and can negatively impact quality of life. Cancer-related fatigue is a very prevalent and distressing long-term side effect among breast cancer survivors that typically improves after completion of treatment, although many patients report severe fatigue several years post-treatment. Cognitive disorders are also common among survivors of breast cancer, especially if treated with chemotherapy. The...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
a Malorni Mutations in the hotspot ligand-binding domain of the estrogen receptor (ER) gene ESR1 have recently been recognized as mechanisms of endocrine resistance in endocrine receptor-positive metastatic breast cancer (MBC). Accumulating data suggest these mutations develop under the selective pressure of endocrine treatments, and are infrequent in untreated ER-positive breast cancers. In vitro studies show that these mutations confer ligand-independent activity, resistance to estrogen deprivation, and relative resistance to tamoxifen and fulvestrant. Post-hoc retrospective and prospective analyses of ESR1 mutations...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study aims to evaluate the antitumour activity of tamoxifen (TAM), a major agent of hormonal therapy for breast cancer, in preclinical GBC model. Quantitative real-time PCR was used to investigate mRNA levels. Protein expression was measured by immunohistochemistry and Western blot. Glycolytic levels were measured by glucose consumption and lactic acid measurement. The antitumour activity of TAM alone or with cisplatin was examined with CCK8 assay, colony formation, flow cytometry and in vivo models. The results revealed that ERÉ‘ expression was higher in GBC tissues and predicted poor clinical outcomes. TAM was showe...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
AbstractPurpose of ReviewThis review will discuss recent important trials for the treatment of HER2-positive breast cancer, emphasize ongoing areas of development, and highlight areas of unmet need.Recent FindingsAdvances for early-stage treatment have been driven by key clinical trials with pertuzumab, neratinib, and TDM-1. In the adjuvant setting, dual HER2 targeting with trastuzumab and pertuzumab has demonstrated modest improvement in disease-free survival. Neratinib also showed modest benefit in the extended adjuvant setting after prior trastuzumab. Finally, for patients who did not achieve pathologic complete respons...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Despite evidence that first-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy improves survival in patients with HR-positive, HER2-positive disease, only 34.9% of patients in this real-world setting received such treatment. Patients with low tumor HR positivity (1%-9%) had lower endocrine therapy use and worse survival than those with high tumor HR positivity (10%-100%). PMID: 31772121 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Effects of chemotherapy found to be more transient in comparison
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Gynecology, Oncology, Pharmacy, Psychiatry, Journal, Source Type: news
Condition:   Breast Cancer Intervention:   Other: Routine Assessment of HRQoL coupled with Therapeutic Information Sponsor:   Centre Georges Francois Leclerc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
MONDAY, Nov. 25, 2019 -- Endocrine therapy reduces the quality of life of breast cancer patients, especially for postmenopausal women, according to a study recently published in the Annals of Oncology. Arlindo R. Ferreira, M.D., of the Institut...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Arimidex | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormones | Liver | Tamoxifen | Urology & Nephrology | Women